...
首页> 外文期刊>Frontiers in Cellular Neuroscience >Inhibition of Spinal Ca 2+-Permeable AMPA Receptors with Dicationic Compounds Alleviates Persistent Inflammatory Pain without Adverse Effects
【24h】

Inhibition of Spinal Ca 2+-Permeable AMPA Receptors with Dicationic Compounds Alleviates Persistent Inflammatory Pain without Adverse Effects

机译:阳离子化合物对脊髓Ca 2 + 渗透性AMPA受体的抑制作用可减轻持续性炎性疼痛,而无不良影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Upregulation of Ca~(2+)-permeable AMPA receptors (CP-AMPARs) in the dorsal horn (DH) neurons of the spinal cord has been causally linked to the maintenance of persistent inflammatory pain. Therefore, inhibition of CP-AMPARs could potentially alleviate an, otherwise, poorly treatable chronic pain. However, a loss of CP-AMPARs could produce considerable side effects because of the crucial role of CP-AMPARs in synaptic plasticity. Here we have tested whether the inhibition of spinal CP-AMPARs with dicationic compounds, the open-channel antagonists acting in an activity-dependent manner, can relieve inflammatory pain without adverse effects being developed. Dicationic compounds, N 1-(1-phenylcyclohexyl)pentane-1,5-diaminium bromide (IEM-1925) and 1-trimethylammonio-5-1-adamantane-methyl-ammoniopentane dibromide (IEM-1460) were applied intrathecally (i.t.) as a post-treatment for inflammatory pain in the model of complete Freund’s adjuvant (CFA)-induced long-lasting peripheral inflammation. The capability of dicationic compounds to ameliorate inflammatory pain was tested in rats in vivo using the Hargreaves, the von Frey and the open-field tests. Treatment with IEM-1460 or IEM-1925 resulted in profound alleviation of inflammatory pain. The pain relief appeared shortly after compound administration. The effects were concentration-dependent, displaying a high potency of dicationic compounds for alleviation of inflammatory hyperalgesia in the micromolar range, for both acute and long-lasting responses. The period of pain maintenance was shortened following treatment. Treatment with IEM-1460 or IEM-1925 changed neither thermal and mechanical basal sensitivities nor animal locomotion, suggesting that inhibition of CP-AMPARs with dicationic compounds does not give rise to detectable side effects. Thus, the ability of dicationic compounds to alleviate persistent inflammatory pain may provide new routes in the treatment of chronic pain.
机译:脊髓背角(DH)神经元中Ca〜(2+)渗透性AMPA受体(CP-AMPARs)的上调与持续性炎性疼痛的维持有因果关系。因此,抑制CP-AMPARs可能会缓解慢性疼痛。但是,由于CP-AMPAR在突触可塑性中的关键作用,CP-AMPAR的丢失可能产生相当大的副作用。在这里,我们测试了用止痛药(以活性依赖性方式起作用的开放通道拮抗剂)抑制脊柱CP-AMPARs是否可以缓解炎症性疼痛,而未产生不良影响。鞘内施用二阳离子化合物,N 1-(1-苯基环己基)戊烷-1,5-溴化二铵(IEM-1925)和1-三甲基铵-5-1-金刚烷-甲基-氨基戊戊烷二溴化物(IEM-1460)在完全弗氏佐剂(CFA)诱导的持久性外周炎症模型中作为炎症性疼痛的后处理。使用哈格里夫斯(Hargreaves),冯·弗雷(von Frey)和野外试验在体内大鼠中测试了除草剂减轻炎症性疼痛的能力。使用IEM-1460或IEM-1925进行治疗可极大地减轻炎症性疼痛。化合物给药后不久出现疼痛缓解。其作用是浓度依赖性的,对于急性和长期反应,在微摩尔范围内均显示出有效的药物化合物缓解微痛范围的炎性痛觉过敏。治疗后疼痛维持时间缩短。用IEM-1460或IEM-1925进行的治疗既不会改变基础的热和机械敏感性,也不会改变动物的运动能力,这表明用双效化合物抑制CP-AMPAR不会引起可检测到的副作用。因此,除草剂减轻持续性炎性疼痛的能力可为慢性疼痛的治疗提供新途径。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号